Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: a Randomize-controlled Study
Latest Information Update: 24 Oct 2024
At a glance
- Drugs Dalpiciclib (Primary) ; Letrozole (Primary)
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 24 Oct 2024 New trial record